|

Quercetin Clinical Trials

5 actively recruiting trials across 2 locations

Also known as: 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one, C.I. Natural Yellow 10, Quercetin 500 mg capsule, NOW pharmacetics, Vitamine P +1 more

Pipeline

Early 1: 1Phase 2: 4

Top Sponsors

  • Mayo Clinic2
  • Washington University School of Medicine1
  • Fudan University1
  • Al-Mustansiriyah University1

Indications

  • Cancer4
  • Aging, Premature1
  • Treatment-resistant Depression1
  • Schizophrenia1
  • Recurrent Multiple Myeloma1

Other2 trials

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Phase 2

Rochester, Minnesota2 trials

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic in Rochester

Phase 2
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

Mayo Clinic in Rochester

Early 1

St Louis, Missouri1 trial

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Washington University School of Medicine

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.